Pediatric diffuse midline gliomas (DMGs) are highly aggressive brain tumors with a universally fatal prognosis, often taking the lives of children within a year of diagnosis. Despite extensive efforts, radiation therapy remains the only treatment that can extend survival, but tumor progression is inevitable. Recent advances in adult cancer research have revealed that a biological process called cellular senescence plays a significant role in how cancers develop, resist treatment, and recur. Senescence is a natural response to stress and plays an important role in normal processes like wound healing and aging. Furthermore, it was once thought to suppress tumors because senescent cells stop dividing. However, new studies reveal that these cells can release proteins—known as the senescence-associated secretory phenotype (SASP) —that can actually promote tumor growth, invasion, and resistance to therapy in adult cancers. These findings have led me to question whether senescence contributes to the aggressive and treatment-resistant nature of DMGs. By exploring this potential connection, my goal is to uncover new mechanisms that drive this deadly disease and identify innovative strategies to stop its progression.